Kreig T, Takehara K: Skin disease: a cardinal feature of systemic sclerosis. Rheumatology (Oxford) 2009, 48(Suppl 3):iii14–iii18.
Silver RM, Miller KS: Lung involvement in systemic sclerosis. Rheum Dis Clin North Am 1990, 16:199–216.
Ramirez A, Varga J: Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. Treat Respir Med 2004, 3:339–352.
Gilliland BC: Systemic sclerosis (scleroderma). In Harrison’s Principles of Internal Medicine, edn 15. Edited by Braunwald E, Fauci AS, Kasper DL, et al. New York: McGraw-Hill, 2001.
Arroliga AC, Podell DN, Matthay RA: Pulmonary manifestations of scleroderma. J Thorac Imaging 1992, 7:30–45.
Ungerer RG, Tashkin DP, Furst D, et al.: Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983, 75:65–74.
Mukerjee D, St George D, Coleiro B, et al.: Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003, 62:1088–1093.
Steen VD, Conte C, Owens GR, Medsger TA Jr: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37:1283–1289.
White B, Moore WC, Wigley FM, et al.: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000, 132:947–954.
Bianchi FA, Bistue AR, Wendt VE, et al.: Analysis of twenty-seven cases of progressive systemic sclerosis and a review of the literature. J Chronic Dis 1966, 19:953–977.
Schurawitzki H, Stiglbauer R, Graninger W, et al.: Interstitial lung disease in progressive systemic sclerosis: high resolution CT versus radiography. Radiology 1990, 176:755–759.
Swensen SJ, Aughenbaugh GL, Myers JL: Diffuse lung disease: diagnostic accuracy of CT in patients undergoing surgical biopsy of the lung. Radiology 1997, 205:229–234.
Remy-Jardin M, Remy J, Wallaert B, et al.: Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests, and bronchoalveolar lavage. Radiology 1993, 188:499–506.
Diot E, Boissinot E, Asquier E, et al.: Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis. Chest 1998, 114:1623–1629.
Launay D, Remy-Jardin M, Michon-Pasturel U, et al.: High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006, 33:1789–1801.
Desai SR, Veeraraghavan S, Hansell DM, et al.: CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 2004, 232:560–567.
Goldin JG, Lynch DA, Strollo DC, et al.: High resolution CT findings in scleroderma-related lung diseases: findings from Scleroderma Lung Study. Chest 2008, 134:358–367.
Kim EA, Johkoh T, Lee KS, et al.: Interstitial pneumonia in progressive systemic sclerosis: serial high-resolution CT findings with functional correlation. J Comput Assist Tomogr 2001, 25:757–763.
Fujita J, Yoshinouchi T, Ohtsuki Y, et al.: Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001, 60:281–283.
Muller NL, Colby TV: Idiopathic interstitial pneumonias: high-resolution CT and histologic findings. Radiographics 1997, 17:1016–1022.
Latsi PI, Wells AU: Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003, 15:748–755.
Lynch DA: Nonspecific interstitial pneumonia: evolving concepts. Radiology 2001, 221:583–584.
Bouros D, Wells AU, Nicholson AG, et al.: Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002, 165:1581–1586.
Kim DS, Yoo B, Lee JS, et al.: The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19:121–127.
Minai OA, Dweik RA, Arroliga AC: Manifestations of scleroderma pulmonary disease. Clin Chest Med 1998, 19:713–731.
Hunninghake GW, Lynch DA, Galvin JR, et al.: Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 2003, 124:1215–1223.
Colby TV, Carrington CB: Interstitial lung disease. In Pathology of the Lung. Edited by Thurlbeck WM, Churg AM. New York: Thieme Medical Publishers; 1995:589–737.
Piper WN, Helwig EB: Progressive systemic sclerosis: visceral manifestations in generalized scleroderma. AMA Arch Derm 1955, 72:535–546.
Fischer A, Swigris JJ, Groshong SD, et al.: Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 2008, 134:601–605.
•• Clements PJ, Roth MD, Elashoff R, et al.: Scleroderma Lung Study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 2007, 66:1641–1647. This was a prospective treatment study of cyclophosphamide in patients with moderate to severe lung involvement showing that there is similar involvement of the lungs in localized, limited, and diffuse patient groups.
Kazerooni EA, Martinez FJ, Flint A, et al.: Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997, 169:977–983.
•• Goh NS, Desai SR, Veeraraghavan S, et al.: Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177:1248–1254. This was a landmark study demonstrating a predictive value to estimating disease extent on CT and patient survival.
Kim HJ, Li G, Gjertson D, et al.: Classification of parenchymal abnormality in scleroderma lung using a novel approach to denoise images collected via a multicenter study. Acad Radiol 2008, 15:1004–1016.
Wells AU, Rubens MB, du Bois RM, Hansell DM: Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. AJR Am J Roentgenol 1993, 161:1159–1165.
Wells AU: High-resolution computed tomography and scleroderma lung disease. Rheumatology (Oxford) 2008, 47(Suppl 5):v59–v61.
Tashkin DP, Elashoff R, Clements PJ, et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655–2666.
Strange C, Bolster MB, Roth MD, et al.: Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008, 177:91–98.
Shah RM, Jimenez S, Wechsler R: Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis. J Thorac Imaging 2007, 22:120–124.
Giacomelli R, Valentini G, Salsano F, et al.: Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002, 29:731–736.
Griffiths B, Miles S, Moss H, et al.: Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002, 29:2371–2378.
Pakas I, Ioannidis JPA, Malagari K, et al.: Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002, 29:298–304.
Davas EM, Peppas C, Maragou M, et al.: Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999, 18:455–461.
Goldin J, Elashoff R, Kim HJ, et al.: Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo. Chest 2009, 136:1333–1340.
•• McLaughlin V: Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford) 2009, 48(Suppl 3):iii25–iii31. This is an excellent article demonstrating the role of PH in the morbidity and mortality of SILD.
Kahan A, Coghlan G, McLaughlin V: Cardiac complications of systemic sclerosis. Rheumatology (Oxford) 2009, 48(Suppl 3):iii45–iii48.
Vonk Noordegraaf A, Naeije R: Right ventricular function in scleroderma-related pulmonary hypertension. Rheumatology (Oxford) 2008, 47(Suppl 5):v42–v43.
Lahcene M, Oumnia N, Matougui N, et al.: Esophageal dysmotility is scleroderma: a prospective study of 183 cases. Gastroenterol Clin Biol 2009, 33:466–469.
Tobin RW, Pope CE 2nd, Pellegrini CA, et al.: Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 158:1804–1808.
Marie I, Dominique S, Levesque H, et al.: Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001, 45:346–354.
Bhalla M, Silver RM, Shepard JA, McLoud TC: Chest CT in patients with scleroderma: prevalence of asymptomatic esophageal dilatation and mediastinal lymphadenopathy. AJR Am J Roentgenol 1993, 161:269–272.